Ibandronic acid 50mg tablets
Requires a prescription from a doctor or prescriber
Drugs affecting bone metabolism
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ibandronic acid
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ibandronic acid
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
17 branded products available
MHRA licensed products
View all licensed products for Ibandronic acid on the MHRA register
Bondronat 50mg tablets
Ibandronic acid 50mg tablets
Ibandronic acid 50mg tablets
Ibandronic acid 50mg tablets
Ibandronic acid 50mg tablets
Ibandronic acid 50mg tablets
Ibandronic acid 50mg tablets
Ibandronic acid 50mg tablets
Ibandronic acid 50mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
5 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Ibandronic acid
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(2)
Bisphosphonates for treating osteoporosis (TA464)
Romosozumab for treating severe osteoporosis (TA791)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
195 found
Half-life
37-157 hours
Mechanism
Bisphosphonates are taken into the bone where they bind to hydroxyapatite.
Food interactions
2 warnings
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.63%
[A203153]
In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h…
Half-life
37-157 hours
[L13805][L13808]
Protein binding
85.7-99.5%
Volume of distribution
90-368L
[A203153][L13805][L13808]…
Metabolism
[L13805][L13808]
Elimination
[A203153][L13805][L13808]
Clearance
84-160mL/min
[L13805][L13808]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Ibandronate was granted FDA approval on 16 May 2003.[L13805]
[L13805][L13808]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 784 interactions
[L13805][L13808]
Oral overdose can be managed by giving patients milk or antacids to bind excess unabsorbed ibandronate.
[L13805]
Overdoses can be managed by providing intravenous electrolytes and dialysis is not expected to remove excess drug from serum.
[L13805][L13808]
Osteoclasts mediate resorption of bone.[A6366] When osteoclasts bind to bone they form podosomes, ring structures of F-actin.[A6366] Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption.[A6366]
Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate.[A202769][A203147] These components are essential for post-translational prenylation of GTP-binding proteins like Rap1.[A202769] The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis.[A202769] ibandronate also activated caspase-3 which contribute to apoptosis.[A203150]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A203153]
In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL.
[A203162]
The Tmax is approximately 1 hour, while Cmax varies depending on dose.
[A203162]
A 2mg intravenous dose of ibandronate has an AUC of 316ng\*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng\*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng\*h/mL.
[A203159]
[L13805][L13808]
[L13808]
[A203153][L13805][L13808]
[L13805][L13808]
[A203153][L13805][L13808]
[L13805][L13808]
Proteins and enzymes this drug interacts with in the body
ATC M05BA06
ATC M05BB09
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Additional database identifiers
Drugs Product Database (DPD)
11519
ChemSpider
54839
BindingDB
12577
PDB
BFQ
ZINC
ZINC000001533877
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4249
GeneCards
GGPS1
GenBank Gene Database
AB017971
GenBank Protein Database
4520350
Guide to Pharmacology
643
UniProt Accession
GGPPS_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3631
GenAtlas
FDPS
GeneCards
FDPS
GenBank Gene Database
J05262
GenBank Protein Database
182399
Guide to Pharmacology
644
UniProt Accession
FPPS_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
All patents expired, 7 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: